Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT05680298
- Locations
- 🇨🇳
Beijing Children's hospital, Beijing, China
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
- Conditions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 146
- Registration Number
- NCT05649579
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT05649098
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT05624112
- Locations
- 🇨🇳
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital), Guangzhou, Guangdong, China
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 926
- Registration Number
- NCT05601882
- Locations
- 🇺🇸
Florida International Rsrch cr /ID# 249667, Miami, Florida, United States
🇨🇳The second affiliated hospital of Zhejiang University school of medicine /ID# 249655, Hangzhou, Zhejiang, China
🇩🇪Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 249560, Lübeck, Schleswig-Holstein, Germany
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT05590585
- Locations
- 🇺🇸
Skin and Cancer Associates, LLP, Miami, Florida, United States
🇺🇸C2 Research Center, LLC, Montgomery, Alabama, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT05575037
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Regeneron AA Multicenter (Dupilumab)
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Emma Guttman
- Target Recruit Count
- 68
- Registration Number
- NCT05551793
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸UR Dermatology at College Town, Rochester, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT05545072
- Locations
- 🇺🇸
Emory Hospital Midtown-Otolaryngology, Atlanta, Georgia, United States
🇺🇸Ambulatory Surgery Center - Emory University Hospital, Atlanta, Georgia, United States
🇺🇸University of Texas Health Science Center at Houston, Houston, Texas, United States
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
- Conditions
- Interventions
- Drug: Squaric Acid Dibutyl EsterOther: Known patch test allergensDevice: MicroneedleDrug: DupilumabDevice: Suction blisteringDrug: AdalimumabProcedure: Skin punch biopsyDrug: UstekinumabDrug: GuselkumabDrug: CanakinumabDrug: SarilumabDrug: Triamcinolone AcetonideDrug: Betamethasone ValerateDrug: Fluticasone Propionate
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- John Harris
- Target Recruit Count
- 45
- Registration Number
- NCT05535738
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.